drugset

drugset / Trial / NCT01208285

Study of VX-770 in Subjects With Moderate Hepatic Impairment and in Matched Healthy Subjects

NCT01208285 ↗

Phase 1 Completed 24 enrolled Vertex Pharmaceuticals Incorporated

Non-randomizedParallel-groupOpen-labelTreatment

Summary

The purpose of this study is to investigate the pharmacokinetics and safety of a single dose of VX-770 in subjects with moderate hepatic impairment.

Timeline

Start: 2010-09
Primary completion: 2010-12
Completion: 2010-12

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Ivacaftor	Other / unclassified	150 mg	Oral

Indications